What is Multiple Sclerosis?

Multiple ⁢Sclerosis (MS) is‌ a ‌chronic,often debilitating disease that‌ affects⁣ teh central nervous⁤ system -⁤ the brain and ‌spinal cord. ⁣Worldwide, approximately 2.8 million people live with MS, facing a ⁤range of symptoms that disrupt daily life.​ The disease occurs when the immune system ‌mistakenly attacks myelin, the ⁢protective sheath surrounding nerve​ fibers, hindering communication between‍ the brain and body.

The Promise of a⁤ Regenerative Approach

Current⁤ MS treatments primarily focus ⁣on ‌slowing disease activity and managing symptoms like fatigue, vision problems, and mobility issues.⁢ Though, they don’t address the existing nerve damage. This new therapy, ‌spearheaded⁢ by Dr. Fang Liu⁣ at CAMH,offers a fundamentally different approach: regeneration.‍ It aims to not⁤ only halt the‍ progression of MS but also actively repair the damage already done.

The therapy targets a process called⁤ excitotoxicity, where excessive ​stimulation of nerve cells leads ​to their damage and death. By selectively blocking excitotoxicity *without* ⁤disrupting normal brain ⁢function, the treatment encourages the ​body’s natural ability to ‌rebuild myelin and⁤ improve nerve recovery.‍ Preclinical studies in animal models have demonstrated significant ⁣restoration of motor⁤ skills ​and myelin repair, even ⁤when the treatment was initiated after symptoms appeared.

How Does the Therapy Work?

excitotoxicity plays a crucial role ‌in the pathology of MS.⁣ When nerve ‌cells⁣ are overstimulated, they release excessive ⁣amounts of glutamate, a neurotransmitter. This overstimulation leads to calcium influx, triggering a cascade of events that ultimately⁢ damage or kill the nerve cell. The ⁤therapy developed by Dr. Liu’s team ​aims to modulate this process, preventing the damaging ⁤effects of ‍excitotoxicity ⁣while preserving⁤ normal neuronal ‌signaling.

The compound’s ability to restore function‌ even *after* symptom onset is particularly noteworthy.⁢ ‌This suggests a⁣ potential for reversing existing disability, ⁣a goal that has ⁤remained‌ elusive in MS treatment. ⁤ The team’s success in animal models provides a‍ strong rationale for moving ⁣forward with human clinical trials.

Funding​ and ⁤collaboration

The project has received substantial funding totaling nearly $800,000 USD ($1,137,868 ⁤CAD) from Brain⁤ Canada, the National⁣ MS Society’s fast Forward program, and ⁢Health Canada through the ⁤canada Brain Research Fund.⁣ This‍ collaborative effort highlights the ⁤importance‍ of⁤ investing in innovative research to address complex neurological disorders.

The research team is a transatlantic ​partnership, led by Dr.Fang Liu, Senior Scientist at CAMH and professor in the Department of Psychiatry⁢ at the University of Toronto, and Dr. Iain‍ Greig, Reader in Medicinal‍ Chemistry at⁣ the​ University of Aberdeen. This collaboration‌ brings together expertise in neuroscience, medicinal chemistry, and clinical translation.

Looking Ahead: Clinical Trials and ‍Potential Impact

The research ⁣team is currently in the final stages of preclinical testing, meticulously preparing for future⁣ human clinical trials. ‍If‌ these trials are successful, ⁣this therapy coudl​ represent Canada’s first regenerative treatment for MS, offering hope⁤ for improved outcomes and quality of life for ​individuals living with the disease.